Literature DB >> 27941538

NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma.

Meera Mahalingam1.   

Abstract

Neurofibromatosis type I (NF1), a monogenic disorder with an autosomal dominant mode of inheritance, is caused by alterations in the NF1 gene which codes for the protein neurofibromin. Functionally, NF1 is a tumor suppressor as it is GTPase-activating protein that negatively regulates the MAPK pathway. More recently, much attention has focused on the role of NF1 and neurofibromin in melanoma as mutations in NF1 have been found to constitute 1 of the 4 distinct genomic categories of melanoma, with the other 3 comprising BRAF, NRAS, and "triple-wild-type" subtypes. In this review, we parse the literature on NF1 and neurofibromin with a view to clarifying and gaining a better understanding of their precise role/s in melanomagenesis. We begin with a historic overview, followed by details regarding structure and function and characterization of neural crest development as a model for genetic reversion in neoplasia. Melanogenesis in NF1 sets the stage for the discussion on the roles of NF1 and neurofibromin in neural crest-derived neoplasms including melanoma with particular emphasis on NF1 and neurofibromin as markers of melanocyte dedifferentiation in desmoplastic melanoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27941538     DOI: 10.1097/PAP.0000000000000131

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  9 in total

1.  Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations

Authors:  Begümhan Demir Gündoğan; Fatih Sağcan; Sevcan Tuğ Bozdoğan; Yüksel Balcı; Ferah Tuncel Daloğlu; Elvan Çağlar Çıtak
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-07-23

Review 2.  Neurofibromatosis: New Clinical Challenges in the Era of COVID-19.

Authors:  Alessio Ardizzone; Anna Paola Capra; Michela Campolo; Alessia Filippone; Emanuela Esposito; Silvana Briuglia
Journal:  Biomedicines       Date:  2022-04-19

3.  Identification of SETD2-NF1 fusion gene in a pediatric spindle cell tumor with the chromosomal translocation t(3;17)(p21;q12).

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Ingvild Lobmaier; Bodil Bjerkehagen; Sverre Heim
Journal:  Oncol Rep       Date:  2017-05-04       Impact factor: 3.906

4.  Pigmented (melanotic) diffuse neurofibroma of the back in neurofibromatosis type 1.

Authors:  Reinhard E Friedrich; Christian Hagel
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2018-08-03

Review 5.  Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma.

Authors:  Ernesto Rossi; Giovanni Schinzari; Brigida Anna Maiorano; Monica Maria Pagliara; Alessandro Di Stefani; Emilio Bria; Ketty Peris; Maria Antonietta Blasi; Giampaolo Tortora
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

6.  Association between neurofibromatosis type 1 and cerebrovascular diseases in children: A systematic review.

Authors:  Beatriz Barreto-Duarte; Fabiana H Andrade-Gomes; María B Arriaga; Mariana Araújo-Pereira; Juan Manuel Cubillos-Angulo; Bruno B Andrade
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

7.  Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy.

Authors:  Samuel Marcrom; Jennifer F De Los Santos; Robert M Conry
Journal:  Clin Sarcoma Res       Date:  2017-07-14

8.  Confocal Microscopy Predicts the Risk of Recurrence and Malignant Transformation of Mucocutaneous Neurofibromas in NF-1: An Observational Study.

Authors:  Giuseppe Giudice; Giorgio Favia; Angela Tempesta; Luisa Limongelli; Michelangelo Vestita
Journal:  Dermatol Res Pract       Date:  2018-09-09

9.  Actin Waves and Dynamic Patterning of the Plasma Membrane.

Authors:  Guenther Gerisch; Jana Prassler; Nelson Butterfield; Mary Ecke
Journal:  Yale J Biol Med       Date:  2019-09-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.